[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Schond L. Greenway net worth and biography

Schond Greenway Biography and Net Worth

CFO of Avalo Therapeutics

Mr. Schond Greenway is the CFO of Avalo Therapeutics.

What is Schond L. Greenway's net worth?: The estimated net worth of Schond L. Greenway is at least $2.92 million as of December 26th, 2023. Mr. Greenway owns 216,617 shares of Avalo Therapeutics stock worth more than $2,919,997 as of November 14th. This net worth approximation does not reflect any other investments that Mr. Greenway may own. Learn More about Schond L. Greenway's net worth.
How do I contact Schond L. Greenway?: The corporate mailing address for Mr. Greenway and other Avalo Therapeutics executives is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. Avalo Therapeutics can also be reached via phone at (410) 522-8707 and via email at [email protected]. Learn More on Schond L. Greenway's contact information.
Has Schond L. Greenway been buying or selling shares of Avalo Therapeutics?: Schond L. Greenway has not been actively trading shares of Avalo Therapeutics within the last three months. Most recently, on Friday, December 10th, Schond L. Greenway bought 9 shares of Avalo Therapeutics stock. The stock was acquired at an average cost of $376.80 per share, with a total value of $3,391.20. Learn More on Schond L. Greenway's trading history.
Who are Avalo Therapeutics' active insiders?: Avalo Therapeutics' insider roster includes Schond Greenway (CFO), Christopher Sullivan (CAO), and H. Wilkins (Insider). Learn More on Avalo Therapeutics' active insiders.
Are insiders buying or selling shares of Avalo Therapeutics?: In the last year, Avalo Therapeutics insiders bought shares 1 times. They purchased a total of 500 shares worth more than $6,250.00. The most recent insider tranaction occured on November, 12th when Director June Sherie Almenoff bought 500 shares worth more than $6,250.00. Insiders at Avalo Therapeutics own 0.3% of the company. Learn More about insider trades at Avalo Therapeutics.
Information on this page was last updated on 11/12/2024.

Schond L. Greenway Insider Trading History at Avalo Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/10/2021	Buy	9	$376.80	$3,391.20

Schond L. Greenway Buying and Selling Activity at Avalo Therapeutics

Avalo Therapeutics Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Today's Range

Now: $13.48

$12.78

$13.59

50 Day Range

MA: $10.64

$7.70

$14.44

2 Week Range

Now: $13.48

$3.95

$34.46

Volume

55,077 shs

Average Volume

214,778 shs

Market Capitalization

$13.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03